24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Multiple Surgeries for Cleft Lip, Palate Won't Cause Major Psychological DamageHIV May Not Worsen COVID-19 OutlookU.S. Coronavirus Hospitalizations Spiking in South, WestAHA News: To Everything There Is a Season, Including Heart DiseaseAsthma, Allergies Plus Pandemic May Pose 4th of July ChallengesStroke Appears 8 Times More Likely With COVID Than With FluCOVID-19 Death Risk Twice as High in New York City as Some CountriesFireworks Are Bad News for Your LungsScientists Find Source of COVID ClotsNew U.S. Coronavirus Cases Top 50,000 as More States Slow Reopening PlansNumbers of Non-COVID-19 Deaths Up During PandemicNo Good Evidence on Accuracy of Coronavirus Antibody Tests: StudyAHA News: COVID-19 Pandemic Brings New Concerns About Excessive DrinkingMuscle Relaxants for Back Pain Are Soaring: Are They Safe?Trauma of Racism Fuels High Blood Pressure Among Black Americans: StudyCOVID-19 Blood Test Might Predict Who Will Need a VentilatorWhat's the Best DIY Face Mask Against COVID-19?Deep Brain Stimulation May Slow Parkinson's, Study FindsU.S. Could See 100,000 New Cases of COVID-19 Each Day, Fauci SaysGlobally, COVID-19 Cases May Stretch Far Beyond Official Numbers: StudyFBI: Beware of Scammers Selling Fake COVID-19 Antibody TestsAHA News: Sadness and Isolation of Pandemic Can Make Coping With Grief HarderVaping-Related Lung Injuries Still Happening -- And May Look Like COVID-19Most With Coronavirus Not Sure How They Caught It: CDCDon't Get Sick While Swimming This SummerAmid Pandemic, Too Many Americans Are Hesitating to Call 911Mask Up! Don't Let Down Your Guard Against COVID-19Wildfire Smoke Causes Rapid Damage to Your Health: StudyCOVID Drug Remdesivir Could Cost Up to $3,120 Per Patient, Maker SaysIntestinal Illness Spurs Recall of Bagged Salads Sold at Walmart, AldiCOVID Threatens the 3 out of 4 Americans Who Can't Work From HomeHispanic Americans Being Hit Hard By COVID-19Global Coronavirus Cases Pass 10 Million as U.S. Struggles With Surge in InfectionsStarted Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: StudyIs 'Pooled' Coronavirus Testing the Next Step for America?U.S. Coronavirus Task Force Warns of Rising Case Numbers, Especially Among YoungWho's at Highest Risk From COVID-19? CDC Updates Its ListStroke, Confusion: COVID-19 Often Impacts the Brain, Study ShowsPromising Results Mean Coronavirus Vaccine Trial Could Start by AugustWhen Can Sports Fans Safely Fill Stadiums Again?Coronavirus Baby Boom? Survey Says Maybe NotCOVID-19 Typically Mild for Babies: StudyU.S. Reports Record Rise in New Coronavirus CasesAHA News: COVID-19 Highlights Long-Term Inequities in Some CommunitiesHow the Saharan Dust Plume Could Make Your Allergies WorseAmid Pandemic, Fears That Older Americans Are Feeling 'Expendable''The Lockdowns Worked,' Experts Say, But Did America Reopen Too Soon?Asymptomatic Coronavirus Carriers Can Shed Virus on Surfaces: StudyVaccine Might Guard Against Bacteria That Cause Diarrhea in KidsOne-Time Treatment Eases Parkinson's -- in Mice
Questions and AnswersLinks
Related Topics

Diabetes

New Drug Helps Shrink Inoperable Tumors in Kids

HealthDay News
by -- Steven Reinberg
Updated: Mar 20th 2020

new article illustration

FRIDAY, March 20, 2020 (HealthDay News) -- A new trial confirms that the drug selumetinib shrinks tumors in children suffering from neurofibromatosis type 1.

The condition is characterized by changes in skin coloring and the growth of tumors along nerves in the skin, brain and other parts of the body. The tumors cause disfigurement, limitations on strength and range of motion, and pain.

The tumors are hard to treat, and they can grow quickly and become up to 20% of a child's weight, the study authors noted.

Surgery is often not an option because the tumors intertwine with healthy nerves and tissue. Even ones that are partially removed tend to grow back, especially in young children.

In the study, children given selumetinib experienced less pain, improved function and overall better quality of life, the researchers reported.

"Until now, no effective medical therapies have existed for children with neurofibromatosis type 1 [NF1] and plexiform neurofibromas, and it's been a long journey to find a drug that can help them," said researcher Dr. Brigitte Widemann. She's chief of the Center for Cancer Research's Pediatric Oncology Branch at the U.S. National Institutes of Health (NIH).

"While this is not yet a cure, this treatment is shrinking tumors and it's making children feel better and have a better quality of life," she said in an NIH news release.

The trial included 50 children, aged 3 to 17, with NF1-related plexiform neurofibromas in 2015 and 2016.

The children were given selumetinib twice a day in 28-day cycles and assessed at least every four cycles.

By March 2019, 70% of the children had a partial response, which was a reduction in the size of the tumors of 20% or more. That response lasted a year or more.

After a year of treatment, children and parents reported less pain and meaningful improvement in daily function, overall quality of life, strength and range of motion, the researchers found.

According to Dr. Andrea Gross, also from the Center for Cancer Research, "One of the most surprising findings of this trial was the impact the treatment had on pain. It even helped patients who had been living with chronic, debilitating pain come off pain medications, which was not something we anticipated. So, that was a really exciting finding."

Five children stopped selumetinib because of possible side effects from the drug, and the disease progressed in six. The most common side effects were nausea and vomiting, diarrhea and rashes, the researchers said.

Widemann pointed out that "there's a lot more to be done. Even though these children have tumor shrinkage, many still have disabling tumors. But these findings are a big step forward and inspire us to work even harder towards additional progress in NF1 therapies."

The report was published March 18 in the New England Journal of Medicine.

More information

For more on NF1, head to the U.S. National Institutes of Health.